Pacira Pharmaceuticals Statement on FDA Advisory Committee for EXPAREL® for Use as a Nerve Block to Produce Regional Analgesia
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Needham & Company Downgrades Pacira Pharmaceuticals (PCRX) to Hold
February 16, 2018 7:20 AM ESTNeedham & Company downgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Buy to Hold.
Analyst Serge Belanger commented, "The FDA's briefing documents presaged a difficult AdCom panel review for Exparel's potential label expansion to nerve blocks. Over the 2-day panel, panel members echoed the FDA's concerns... More
Pacira Pharmaceuticals (PCRX) PT Lowered to $32 at BMO Capital
February 16, 2018 6:11 AM ESTBMO Capital lowered its price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $32.00 (from $41.00) while maintaining a Market Perform rating.
Analyst Gary Nachman commented, "FDA panel voted against approving the nerve block (NB) indication for Exparel (6 No, 4 Yes). We anticipated a complicated... More
Pacira Pharma (PCRX) to Resume Trading at 4:15 pm ET
February 15, 2018 3:51 PM ESTPacira Pharma (NASDAQ: PCRX) to Resume Trading at 4:15 pm ET
... More